| The Panel on Opportunistic Infections in Children with and Exposed to HIV (the Panel) updated the Guidelines for the Prevention and Treatmen |
Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV | The Panel on Opportunistic Infections in Children with and Exposed to HIV (the Panel) updated the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV. Highlights from the updated sections are summarized below: Added recommendations for dolutegravir- and raltegravir-based antiretroviral (ARV) regimens in the context of tuberculosis (TB) disease for children >20 kg and <20 kg, respectively. Added references to American Academy of Pediatrics (AAP) guidance that recommends interferon-gamma release assays (IGRAs) to diagnose latent tuberculosis infection (LTBI) in children â¥2 years old. Added recommendations that children â¥2 years old with HIV infection who are receiving ARV regimens with acceptable drug-drug interactions with rifapentine can receive the 12-dose isoniazid-rifapentine LTBI treatment regimen. For a list of recent updates, please see What's New in the Guidelines. To view or download the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV, go to the Clinicalinfo website. The guidelines tables and recommendations also can be downloaded as separate PDF files. Clinicalinfoâ¯welcomes your feedbackâ¯on the latest revisions to the Guidelines for the Prevention and Treatment of Opportunistic Infections in Children with and Exposed to HIV. Please send your comments with the subject line âPediatric Opportunistic Infections Guidelinesâ to [email protected] by October 5, 2023. |
|
|
|
|
Â
You are subscribed as [email protected]. Â Update your subscriptions, modify your password or email address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your email address to log in. If you have questions or problems with the subscription service, please visit the GovDelivery Subscriber Help Center at https://insights.govdelivery.com/Communications/Subscriber_Help_Center.
This service is provided in collaboration with NIHâs Office of AIDS Research and HHS Office of Infectious Disease and HIV/AIDS Policy/HIV.gov.
| This email was sent to [email protected] using GovDelivery Communications Cloud on behalf of: HIVinfo · 8600 Rockville Pike · Bethesda, MD 20894 · 888-346-3656 | |
